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Summary Docetaxel and ifosfamide have shown significant activity against a variety of solid tumours. This prompted a phase I trial on the
combination of these drugs. This phase I study was performed to assess the feasibility of the combination, to determine the maximum
tolerated dose (MTD) and the side effects, and to propose a safe schedule for further phase 11 studies. A total of 34 patients with a
histologically confirmed solid tumour, who were not pretreated with taxanes or ifosfamide and who had received no more than one line of
chemotherapy for advanced disease were entered into the study. Treatment consisted of docetaxel given as a 1-h infusion followed by
ifosfamide as a 24-h infusion (schedule A), or ifosfamide followed by docetaxel (schedule B) every 3 weeks. Docetaxel doses ranged from 60
to 85 mg m-2 and ifosfamide doses from 2.5 to 5.0 g m-2. Granulocytopenia grade 3 and 4 were common (89%), short lasting and ifosfamide
dose dependent. Febrile neutropenia and sepsis occurred in 17% and 2% of courses respectively. Non-haematological toxicities were mild to
moderate and included alopecia, nausea, vomiting, mucositis, diarrhoea, sensory neuropathy, skin and nail toxicity and oedema. There did
not appear to be any pharmacokinetic interaction between docetaxel and ifosfamide. One complete response (CR) (soft tissue sarcoma) and
two partial responses (PRs) were documented. A dose of 75 mg m-2 of docetaxel combined with 5.0 g m-2 ifosfamide appeared to be
manageable. Schedule A was advocated for further treatment.
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Docetaxel is a new antimicrotubule agent that enhances polymer-
ization oftubulin into stable microtubules and inhibits microtubule
depolymerization. This induces a disruption of the equilibrium
within the microtubule system and ultimately leads to cell death
(Gueritte-Voegelein et al, 1991; Ringel et al, 1991; Rowinsky et al,
1991). Docetaxel has been studied in many murine tumour models,
showing activity against subcutaneous (s.c.) B16 melanoma, MX-l
mammary cancer, C38 colon carcinoma, CX-1 colon carcinoma,
LX-1 lung carcinoma, s.c. early stage pancreatic ductal adenocarci-
noma (P03), S.C. colon adenocarcinoma 51 (C51), SK MEL-2
melanoma and OVCAR-3, HOC 8, HOC 10 and HOC 22 ovarian
carcinomas (Denis et al, 1988; Bissery et al, 1991; Harrison et al,
1992, Nicoletti et al, 1992). In phase I studies on single-agent
docetaxel the major dose-limiting toxicity (DLT) was neutropenia
that appeared to be short lasting, dose dependent, schedule inde-
pendent andnon-cumulative (Aapro et al, 1992; Pazdur et al, 1992;
Bisset et al, 1993; Burris et al, 1993; Extra etal, 1993; Tomiaket al,
1993). Based on these phase I studies, the recommended single-
agent dose and schedule for docetaxel was 100 mg m-2 given as a
1-h infusion every 3 weeks. Phase II studies on docetaxel showed
activity in breast cancer (Seidman et al, 1993; Ten Bokkel-Huinink
et al, 1994; Trudeau et al, 1993; Valero et al, 1993; Chevallier et al,
1995), non-small-cell lung cancer (Cemy et al, 1994; Fossella et al,
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1995; Miller et al, 1995), head and neck cancer (Catimel et al,
1994), gastric cancer (Sulkes et al, 1994), melanoma (Aamdal et al,
1994), soft tissue sarcoma (Van Hoesel et al, 1994) and pancreatic
cancer (De Fomi et al, 1994). The most important side-effect was
an early and short-lasting neutropenia, which in 20% ofthe patients
was complicated by infection (Pronk et al, 1995). Alopecia was a
common side-effect and usually universal. Gastrointestinal side-
effects such as nausea, vomiting, diarrhoea and mucositis were
mild and easily treated. Other side-effects included asthenia, infre-
quent hypersensitivity reactions, skin reactions, nail changes, mild
sensory neuropathy and fluid retention. The application ofpremed-
ication consisting ofcorticosteroids has markedly reduced the inci-
dence of hypersensitivity reactions (Schrijvers et al, 1993) and
seems to decrease the severity of fluid retention (Piccart et al,
1994). Therefore, most studies on docetaxel are now performed
with standard corticosteroid premedication.
Ifosfamide is an alkylating drug that among others has shown to
be active against non-small-cell lung cancer (Ettinger, 1989),
testicular cancer (Kaye et al, 1995), breast cancer (Hoffmann et al,
1990) and soft tissue sarcoma (Pinedo et al, 1986). The main side-
effects of ifosfamide consist of urotoxicity, nephrotoxicity, neuro-
toxicity, myelosuppression, nausea, vomiting' and alopecia.
Ifosfamide can be administered orally or intravenously as a bolus
or as a continuous infusion over 1-5 days. Standard single-agent
doses range between 5 and 10 g m-2. In the present study,
Ifosfamide was given as a continuous 24-h infusion for the
patient's convenience. The combination of these two drugs could
be ofmajor interest in tumours in which they are both effective.
Thisphase I study onthecombination ofdocetaxel andifosfamide
was performed with the following objectives: (a) to determine the
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maximum tolerated dose (MTD); (b) to characterize the toxic
effects: (c) to determine the optimal drug administration sequence;
(d) to propose adose and sequence forfurtherphase II studies; (e) to
report any anti-tumour effect of the docetaxel-ifosfamide combina-
tion; and (f) to describe pharmacokinetics of both drugs in this
particularcombination. Theresults ofthe lasttopic will be published
elsewhere. Rowinsky et al (1991) demonstrated the importance and
potential relevance ofdrug sequence and therefore sequence investi-
gations should be integrated in all phase I studies involving combi-
nations ofdrugs.
PATIENTS AND METHODS
Eligibility
Only patients with a histologically confirmed solid tumour for
which no therapies with greater potential benefit than docetaxel
and ifosfamide existed were candidates for this study. Eligibility
criteria included: (a) age 2 18 years and < 75 years; (b) WHO
performance status 0-2; (c) no more than one line of previous
chemotherapy for advanced disease, previous (neo) adjuvant
chemotherapy was allowed provided that this chemotherapy had
ended at least 6 months before study entry; (d) no previous anti-
cancer therapy for more than 4 weeks (6 weeks in cases ofnitros-
ureas, mitomycin C and carboplatin); (e) no previous treatment
with docetaxel, ifosfamide or paclitaxel; (f) no previous radio-
therapy for at least 4 weeks (8 weeks in cases of extensive
previous radiotherapy); (g) adequate bone marrow (neutrophils
2 2 x 1091-1, platelets 2 100 x 1091-', hepatic (total bilirubin < 1.25
times the upper-normal limits, ASAT (SGOT) < 2 times and in
case ofproven liver metastases < 3 times the upper-normal limits)
and renal function (serum creatinine < 120,mol 1-1); (h) absence
ofsymptomatic peripheral neuropathy 2 grade 2 according to NCI
Common Toxicity Criteria (CTC) (Brundage et al, 1993); and (i)
no peptic ulcer, unstable diabetes mellitus or other contra-
indications for the use of corticosteroids. All patients had to give
written informed consent.
Drug administration
Docetaxel (Taxotere-RP 56976) was supplied by Rh8ne-Poulenc
Rorer (Antony, France) as a concentrated sterile solution
containing 40 mg ml-' = 80 mg per 2 ml per vial in polysorbate 80
(Tween 80). The appropriate amount of the drug to be adminis-
tered to the patient was diluted in 5% dextrose or 0.9% saline solu-
tion so that the maximum docetaxel concentration was 1 mg ml-'.
The drug was administered to the patient as a 1-h i.v. infusion.
Ifosfamide (ASTA, Degussa, Frankfurt, Germany) was diluted
in a 3-1 dextrose saline solutionplus mesna and administered to the
patient as a 24-h i.v. continuous infusion. Treatment cycles were
repeated every 3 weeks.
Routine comedication
All patients received 32 mg of methylprednisolone or 8 mg of
dexamethasone orally 12 and 3 h before docetaxel infusion and
then 12 and 24 h after the end of docetaxel infusion, followed by
either 32 mg or 8 mg twice daily for an additional 3 days to
prevent the onset of hypersensitivity reactions and to reduce
and/or delay the occurrence of skin toxicity and/or fluid retention
related to docetaxel.
Schedule A
Mesna
bolus
Doce- 0.51
axel saline I Ifosfamide + mesna Saline + mesna vx.
4 A 1A - A
0 1 2 0 2 1
day 1 day 2
Molsa Schedule B
11 Doce-
saline Ifosfamide + mesna Saline + mesna taxel
I I
0 2 0 2 14h 0 1 h
day 1 day 2 day 3
Figure 1 Drug administration sequence
Prophylactic co-medication with mesna was given to allpatients
to prevent urotoxicity induced by ifosfamide. The mesna dose was
adapted according to the ifosfamide dose and was fractionated in
an i.v. bolus of 20% of the corresponding ifosfamide dose given
just before ifosfamide administration, 50% of the dose given
concomitantly with the ifosfamide solution and 20% ofthe dose in
a 2-1 dextrose saline solution given as a 12 h infusion after the end
ofifosfamide administration.
All patients received prophylactic i.v. antiemetic medication
with a 5-HT3 antagonist in a dose of either 8 mg of ondansetron,
5 mg of tropisetron or 3 mg of granisetron, just before the first
cytotoxic drug administration and then once a day orally during
the two following days in the same dose.
Dosage
The docetaxel and ifosfamide doses were escalated according to a
pre-established schedule and according to the toxicities observed
at the previous dose level, after a minimum of three patients had
tolerated the previous dose. Toxicities were graded according to
the NCI Common Toxicity Criteria (CTC) (Brundage et al, 1993).
Once a patient in a given dose level developed side-effects of
CTC 2 grade 3, other than myelosuppression, an additional three
patients were entered at the same dose level. Dose-limiting toxi-
city (DLT) was defined as CTC 2 grade 3 toxicity (excluding
myelotoxicity) observed in 2 three patients at a given dose level.
For myelosuppression DLT was defined as: (a) granulocytes
< 0.5 x 109 1-1 for > 7 days; (b) granulocytes < 1.0 x 109 1- with
fever 2 380C lasting > 3 days; (c) platelets < 25 x 109 1-'; and
(d) infections 2 grade 3 requiring hospitalization.
The maximum tolerated dose (MTD) was defined as the dose
level at which at least three out of six patients developed the same
dose limiting toxicity. In this study MTDs could be determined for
both drug sequences.
The following dose levels ofdocetaxel/fosfamide were explored:
level I 60 mg m-2/2.5 g-' m-2; level II, 75 mg m-2/2.5 g m-2; level
III, 75 mg m-2/3.0 g-' m-2; level IV, 75 mg m-2/4.0 g-I m-2; level V,
75 mg m-2/5.0 g-I m-2; level VI, 85 mg m-2/5.0 g-' m-2; level VII,
100 mg m-2/5 g-I m-2.
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Drug sequence
Dose escalation was initially performed with docetaxel preceding
ifosfamide (schedule A) with a 1-h interval between the end of
docetaxel infusion and the start ofifosfamide (Figure 1). When the
MTD and doses to be used for further phase II studies were deter-
mined for schedule A, the dose level just below the MTD was
reassessed with ifosfamide preceding docetaxel (schedule B). In
this schedule there is a 24-h interval between the end ofifosfamide
infusion and the start ofdocetaxel infusion. When the toxicities in
this schedule were acceptable, further dose escalation was pursued.
Pretreatment and follow-up studies
Before the start of treatment medical history was taken and phys-
ical examination including neurological examination, laboratory
studies, ECG, chest radiograph and if appropriate computerized
tomography (CT) scan were performed.
Laboratory studies included acomplete blood count, differential
white blood cell (WBC) count, sodium, potassium, chloride,
bicarbonate, creatinine, urea, magnesium, calcium, total protein,
albumin, alkaline phosphatase, bilirubin, gamma-glutamyltrans-
ferase (y-GT), lactate dehydrogenase (LDH), aspartate transami-
nase (ASAT) (SGOT), alanine transaminase (ALAT) (SGPT),
glucose, uric acid and urinalysis.
History, physical examination, toxicity scoring (according to
NCI CTC) (Brundage et al, 1993) were performed every 3 weeks
and laboratory studies weekly. Complete blood counts were
performed every week and every 2 days in case of febrile
neutropenia. Urinalysis was performed before, during and after
ifosfamide administration in every cycle. Every 3 weeks ECG was
repeated. Chest radiographs and formal tumour assessments were
performed after every two courses of chemotherapy. Standard
WHO response criteria (WHO Handbook 1979) were used.
RESULTS
Thirty-four patients were entered in this study. Patients character-
istics are given in Table 1. All patients were evaluable for toxicity
and tumour response.
Table 2represents thedose level studied, thenumberofpatients at
each dose level and the number of evaluable courses at each dose
level. Fifteen patients were treated at more than one dose level
because ofdose reduction because ofvarious toxicities. Ten ofthese
fifteen patients underwent dose reduction after the first treatment
cycle because of neutropenic fever. The other five patients under-
went dose reduction after two or more courses. Twopatients at dose
level VIA underwent three and four dose reductions respectively.
The number between brackets represents the number of patients
who were initially treated at a higher dose level and underwent dose
reduction. A total of 155 courses were assessable for toxicity. No
dose-limiting toxicities were observed for cycle 1 in dose levels IA
and IIA. Serious toxicities were reported in cycle 1 at the following
dose levels: febrile neutropenia at dose levels IIIA-VIA and IVB;
diarrhoea grade 4 at dose level VA; and vomiting grade 3 at dose
level IVB. A septic death was reported at dose level VA.
Haematological toxicity
Table 3 represents the relevant haematological toxicities.
Granulocytopenia grades 3 and 4 were observed at all dose levels
in 89% of courses and appeared to be ifosfamide dose-dependent.
Table 1 Patient characteristics
Characteristics Number
Patients treated: 34
Age (years)
Median 53
Range (26-69)
WHO performance status:
Median 1
Range (0-1)
Sex
Male 24
Female 10
Previous chemotherapy treatment
None 11
One regimen 23
Tumour type
Head and neck cancer 5
Non-small cell lung cancer 5
Malignant melanoma 5
Soft tissue sarcoma 3
Malignant mesothelioma 3
Primary unknown 2
Colon cancer 2
Miscellaneous 9
Table 2 Patient accrual
Dose Docetaxel Ifosfamide Number of Number of cycles
level (mg r-2) (g r-2) patlents* (range)
IA 60 2.5 3 (1) 7 (1-2)
11 A 75 2.5 3 (3) 29 (1-10)
lIlA 75 3.0 6 (4) 24 (1-9)
IV A 75 4.0 6 (5) 32 (1-8)
V A 75 5.0 7 (3) 33 (1-14)
VI A 85 5.0 3 5 (1-3)
III B 75 3.0 -(3) 8(1-4)
IVB 75 4.0 6 17(1-6)
Total 34 155
*Patients initially treated at a higher dose level.
In schedule A, febrile neutropenia associated with hospital admis-
sion occurred in 15% of courses of which only one course was
associated with sepsis. The granulocyte nadir was normally
observed between days 8 and 11 ofthe course and lasted less than
7 days. Severe anaemia grades 3 and 4 were only documented in
6% of the courses. Thrombocytopenia grades 1 and 2 were
observed at all dose levels but grades 3 and 4 were not reported.
In schedule B, granulocytopenia grades 3 and 4 were docu-
mented in 77% of the courses. Febrile neutropenia occurred in
18% of the courses, whereas only two courses were complicated
by sepsis. Severe anaemia and thrombocytopenia grades 3 and 4
were uncommon.
Non-haematological toxicity
The most common non-haematological toxicities are shown in
Table 4. Alopecia was common and occurred at all dose levels.
Nausea and vomiting were usually mild and were reported in 41%
and 25% of courses respectively. In schedule B grade 3 vomiting
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Table 3 Haematological toxicity
Dose level
I A IIA IIIA IVA VA VIA III B IV B Total(%)
Number of assessable patients* 3 (1) 3 (3) 6 (4) 6 (5) 7 (3) 3 - (3) 6 34
Courses assessable for haematological toxicity 7 29 24 32 33 5 8 17 155
Number courses with
Grade 3 neutropenia - 8 4 1 - - 1 3 17 (11)
Grade4neutropenia 3 18 17 30 33 5 5 10 121 (78)
Febrile neutropenia - 3 3 8 7 2 - 3 26 (17)
Grade 1-2 thrombocytopenia 2 1 1 1 8 1 - 1 15 (10)
Grade 3-4 thrombocytopenia - - - - - - - - 0 (0)
*Patients initially treated at a higher dose level.
Table 4A Non-haematological toxicity
Dose level
IA IIA IIIA IVA VA VIA III B IVB Total(%)
Number of assessable patients* 3 (1) 3 (3) 6 (4) 6 (5) 7 (3) 3 - (3) 6 34
Number of assessable courses 7 29 24 32 33 5 8 17 155
Number of courses with
Nausea grade 1/2 5 1 9 13 13 5 7 11 64 (41)
Nausea 2 grade 3 - - - - - - - - 0 (0)
Vomiting grade 1/2 - - 2 7 11 5 4 9 38 (25)
Vomiting 2 grade 3 - - - - - - 2 1 3 (2)
Mucositis grade 1/2 - 3 2 7 11 2 3 9 37 (24)
Mucositis 2 grade 3 - - - - - 1 1 - 2 (1.3)
Diarrhoea grade 1/2 - 1 3 2 1 2 - 3 12 (8)
Diarrhoea 2 grade 3 - - - - 1 - - - 1 (0.6)
Myalgia - 4 3 7 - 1 1 3 19 (12)
Allergy - - 1 - - - 1 5 7 (5)
*Patients initially treated at a higher dose level
Table 4B
IA IIA IIIA IVA VA VIA IIIB IVB Total(%)
Number of assessable patients* 3 (1) 3 (3) 6 (4) 6 (5) 7 (3) 3 - (3) 6 34
Number of patients with
Alopecia grade 1/2 3 3 (1) 5 (1) 5 (1) 6 3 - 6 34 (100)
Asthenia grade 1/2** 2 3 (1) 2 (2) 4 (1) 4 1 - 6 26 (76)
Astheniagrade3** - - - 1 - - - - 1 (3)
Cutaneous - 1 2 3 3 1 2 1 13 (38)
Nails - 1 (1) -(1) 1 1 (1) - 1 1 8 (24)
Oedema grade 1/2** - 1 (1) - - 2 - - 1 5 (15)
Neurosensory grade 1/2 - 2 1 (1) 4 6 (1) 1 - 3 19 (56)
Neurocortical - - - - - - - - 0 (0)
*Patients initially treated as a higher dose level; "grade 1, mild; grade 2, moderate; grade 3, severe.
was observed in three courses. Diarrhoea grades 1 and 2 occurred in 56% of patients. However, no neurocortical toxicities such as
in 8% ofcourses, being severe (grade4) in only one course at dose ifosfamide-induced encephalopathy were observed. Docetaxel-
level VA. Mucositis grades 1 and 2 were documented in 24% of related toxicities such as skin and nail changes and oedema were
courses, being severe in one course at dose level VIA and in one mild and never a reason to stop therapy. They occurred in 38%,
course at dose level IIIB. The incidence ofgastrointestinaltoxicity 24% and 15% ofpatients respectively. Hypersensitivity reactions
appeared to behigher in schedule B. Asthenia occurred at all dose were mild to moderate and consisted offlushing and dyspnoea in
levels and was not related to the schedule. The docetaxel-ifos- somepatients. They only occurred in 5% ofcourses but were more
famide combination induced amild, sensoryneuropathygrade 1-2 frequent in schedule B.
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RESPONSES
A histologically proven complete response (CR) was achieved in a
patient with a soft tissue sarcoma treated at dose level II. Partial
responses were observed in cancer of unknown primary and in
non-small-cell lung cancer, one patient each.
DISCUSSION
Docetaxel is a new antimicrotubule agent that has already demon-
strated activity in a wide variety of solid tumours and was regis-
tered for use in advanced breast cancer in 1995. Ifosfamide is an
alkylating agent that is active when administered orally in non-
small-cell lung cancer, testicular cancer, breast cancer and
sarcoma. Because of the partly overlapping toxicity profiles and
their activity against a wide range of solid tumours it was consid-
ered of interest to pursue a combination regimen of these two
drugs. This phase I study was performed to assess the feasibility of
the combination, to determine the MTD and the side-effects and to
evaluate iftoxicity is drug sequence dependent.
No phase I studies on the combination docetaxel-ifosfamide
had been performed previously. The major toxicity of the combi-
nation was granulocytopenia grades 3 and 4, which occurred in
89% of all courses and appeared to be ifosfamide dose dependent.
Neutropenia grade 4 associated with fever occurred in 17% of all
courses and was more common at the highest dose levels. The
DLT for schedule A was neutropenic fever at a dose of 85 mg m-2
ofdocetaxel and 5 g m-2 of ifosfamide (dose level VIA). The DLT
for schedule B was neutropenic fever at a dose level of 75 mg m-2
of docetaxel and 4 g m-2 of ifosfamide (dose level IVB), which
was the initial dose tested. This observation cannot be explained
by a difference in haematological toxicity between schedule A and
B or by a difference in patient selection. As this made clear that
there was no obvious advantage of this schedule compared with
schedule A, no further patients have been studied.
The most common non-haematological toxicities were nausea,
vomiting, mucositis and diarrhoea, most of them being mild.
Schedule B appeared to induce more gastrointestinal toxicity than
schedule A, for which no explanation can be given. In 19 out of 34
evaluable patients (56%) the docetaxel-ifosfamide combination
induced a sensory neuropathy grade 1-2, whereas no neurocortical
toxicity was observed. The incidence of sensory neuropathy of the
combination was slightly higher than the incidence reported for
docetaxel as a single agent (49%) (Hilkens et al, 1996). In a phase
I study combining paclitaxel and cisplatin (Rowinsky et al, 1991)
and in a phase I study on the docetaxel-cisplatin combination
(Hilkens et al, 1997; Pronk et al, 1997), the incidence of sensory
neuropathy of the combination was higher than that reported for
docetaxel as a single agent (Hilkens et al, 1996). It was suggested
that these agents act synergistically in producing neurotoxicity.
The incidence ofdocetaxel related toxicities such as hypersensi-
tivity reactions, nail and skin toxicity and oedema was relatively
low and never a reason for treatment discontinuation. In this study,
all patients received premedication consisting of dexamethasone
or methylprednisolone, which might account for the low incidence
of the above-mentioned side-effects.
Anti-tumour responses were seen in a variety oftumour types at
all dose levels. Of note, was the histologically proven complete
response in a patient with soft tissue sarcoma.
Based upon the data obtained in this phase I study the recom-
mended dose for phase II studies will be 75 mg m-2 of docetaxel
combined with 5 g m-2 of ifosfamide. Schedule A is advocated for
further treatment because this schedule is more manageable and
seems to induce less gastrointestinal toxicity than schedule B.
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